ACTG A5188(V 10):TRNSDRML CNTRACPTV SYSTM&ORAL CNTRACPTV IN HIV-1 WOMEN W/L/R

ACTG A5188(V 10):TRNSDRML CNTRACPTV 系统

• 批准号: 7377850
• 负责人: MONICA CARTEN
• 金额: $ 1.01万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377850
• 关键词: ACTG; A5188; 10; TRNSDRML; CNTRACPTV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at hormone levels in the body after taking two different types of birth control, the ORTHO EVRA patch and the ORTHO NOVUM pill. It is not known if taking ORTHO EVRA or ORTHO NOVUM and anti-HIV medication at the same time will change the amount of hormone or anti-HIV drug levels in a woman's body. The Food and Drug Administration (FDA) has approved ORTHO EVRA and ORTHO NOVUM for contraception, but they have not yet been tested in HIV-1 infected women taking Kaletra. The ORTHO EVRA patch and one ON 1/35 tablet will be supplied by the study. All participants will receive one ON 1/35 pill and then receive the ORTHO EVRA patch weekly for 3 weeks. Anti-HIV drugs, including Kaletra, are not supplied by the study. See Schema below:

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究将观察服用两种不同类型的避孕药--奥托-埃夫拉贴片和奥托诺-诺姆避孕药后体内的荷尔蒙水平。目前尚不清楚同时服用Ortho Evra或Ortho Novum和抗艾滋病毒药物是否会改变女性体内的荷尔蒙或抗艾滋病毒药物水平。美国食品和药物管理局(FDA)已经批准Ortho Evra和Ortho Novum用于避孕，但它们尚未在服用Kaletra的HIV-1感染妇女身上进行测试。Ortho Evra贴片和1/35片剂将由该研究提供。所有参与者将收到1片1/35的药片，然后每周接受Ortho Evra贴片，为期3周。包括Kaletra在内的抗HIV药物不是由该研究提供的。请参阅下面的架构：